VRCI Verici Dx Plc

TIDMVRCI

RNS Number : 5972R

Verici Dx PLC

02 March 2023

Verici Dx plc

("Verici Dx" or the "Company")

Verici Dx achieves CLIA Certificate of Compliance for full commercial launch of Tutivia(TM)

Successful CMS review and inspection solidify commercial positioning and

represents a major milestone toward US Medicare reimbursement

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully progressed its Registration status to Compliance Certification by the Centers for Medicare & Medicaid ("CMS') for its commercial clinical operations to 45 US states . This follows the inspection by CMS of the Company's US clinical laboratory based at the Innovation Park in Franklin, Tennessee.

The Company now intends to expand commercialisation of its advanced kidney transplant service offerings including Tutivia(TM). This milestone of certification is also a key requirement to obtaining insurance reimbursement coverage under Medicare under the Local Coverage Determination application being submitted this year.

The Company launched its first product, Tutivia(TM), for the detection of early acute rejection in kidney post-transplant patients, in January 2023. This CLIA certification increases the ease of ordering a Tutivia(TM) test from laboratories at transplant medical centres and provides further validation of Verici's tests and services for transplant clinicians across the United States.

The Company will now proceed with its plan towards full accreditation in the remaining five states, including New York, which have further compliance requirements .

The CLIA certification further exemplifies Verici's commitment to a quality-focused approach to providing advanced kidney transplant diagnostics services to clinicians and patients in need.

Sara Barrington, CEO of Verici Dx, said:

" This milestone is an enabling step in our ability to offer our two leading diagnostic tests, Tutivia (TM) and Clarava(TM), on a national basis to patients and their clinicians. We are well positioned to achieve additional milestones and progress commercial initiatives in 2023 that will support our growth in the United States."

Verici Dx will give further progress and strategy updates later this month .

Enquiries:

 
Verici Dx                                                        www.v ericidx .com 
Sara Barrington, CEO                                                Via Walbrook PR 
Julian Baines, Chairman 
 
Singer Capital Markets (Nominated                             Tel: +44 20 7496 3000 
 Adviser & Broker) 
Aubrey Powell / Sam Butcher 
 
Walbrook PR Limited                Tel: +44 20 7933 8780 or vericidx@walbrookpr.com 
Paul McManus / Stephanie Cuthbert                  Mob: +44 7980 541 893 / +44 7796 
 /                                                                        794 663 / 
 Sam Allen                                                            07502 558 258 
 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSSDEEFEDSELD

(END) Dow Jones Newswires

March 02, 2023 02:00 ET (07:00 GMT)

Verici Dx (LSE:VRCI)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Verici Dx (LSE:VRCI)
Historical Stock Chart
Von Jan 2024 bis Jan 2025